Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AGX9903
- Development stage
- Preclinical
- Lead developer
- CCP
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AGX9903 is a generic oral liquid drug candidate developed by Agenix Pharmaceuticals. It is part of a portfolio of niche generic products (including AGX9901 through AGX9905) intended for the United States market via the Abbreviated New Drug Application (ANDA) regulatory pathway. The specific active pharmaceutical ingredient (API) and therapeutic indication for AGX9903 have not been publicly disclosed by the developer. According to the company's development timeline, the project has progressed through market research and R&D into the CDMO (Contract Development and Manufacturing Organization) phase, with target filing dates originally projected for the 2020-2021 period.
- Other names
- AGX9903AGX-9903AGX 9903
Beyond the preview
Go deeper on AGX9903.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AGX9903.